Page 3 - Fast Track Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesMemorial sloan kettering cancer centerNew yorkMartins tallmanMartin tallmanWalter klempSloan ketteringJenene thomasRoberth lurie comprehensive cancer centerPrnewswire moleculin biotech incMyeloid leukemia panelExchange commissionSecurities exchangeNational comprehensive cancer networkWeill cornell medical collegeDrug administration

Long-term Complete Response to Can-Fite s Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article.

United statesMotti farbsteinAmerican cancer societyDrug administrationData monitoring committeeFite biopharma ltdEuropean medicines agencyCan fite biopharmaTherapeutic medicine journalCancer studyCan fite phaseChild pughIndependent data monitoring committeeOrphan drugFast track statusFite biopharma

Moleculin Biotech (MBRX) Announces EMA Grants Orphan Drug Designation for Treatment of Acute Myeloid Leukemia

Moleculin Biotech (MBRX) Announces EMA Grants Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Walter klempDrug administrationEuropean medicines agencyMoleculin biotech incEuropean unionTrademark officeMoleculin biotechOrphan drug designationChief executive officerFast track status

Cyclo Therapeutics : Corporate Presentation

NASDAQ: CYTH cyclotherapeutics.com Forward-Looking Statements 2 .

United statesSouth africaBenny liuGeraldf coxSharonh hrynkowMichael lisjakKaren mullenCaroline hastingsRita colwellLori gorskiJeffreyl tateUniversity professorNational medal of scienceUniversity of the witwatersrandKantar healthTessellon inc

Moleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AML

Pharmaceutical company Moleculin Biotech, Inc. (MBRX) announced Thursday that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of Acute Myeloid Leukemia (AML).

Moleculin biotech incDrug administrationEuropean medicines agencyMoleculin biotechOrphan drug designationAcute myeloid leukemiaFast track status